One of the essential roles of the manufacturer in pharmaceutical manufacturing is ensuring the safety, quality, and sterility of the medicines manufactured. It becomes especially crucial when the medicines manufactured need to be sterilized, and contamination might have a negative effect on the health of patients. EU GMP Annex 1 Manufacture of Sterile Medicinal Products outlines the principles of contamination control and sterility maintenance during production.

Annex 1, updated in August 2024, stands for the significant change in the expectations concerning the manufacturing of sterile pharmaceutical products. The new Annex 1 emphasizes the importance of proactive and science-based contamination control approach as compared to end-product testing.

What Is GMP Annex 1?

Annex 1 of GMP is part of the Good Manufacturing Practice guidelines of the European Union, and focuses on the manufacture of sterile medicinal products. The objective is to reduce the risk of contamination by microbes, particles, and endotoxins/pyrogens.

The guidelines cover various types of sterile products and processes like aseptic processing, terminal sterilization, sterile filling, production of sterile components, and others.

One of the key concepts included in the updated Annex 1 is that sterility should be assured as an inherent feature of the manufacturing process. It is not possible for manufacturers to depend on the test for sterility only.



Contamination Control Strategy (CCS)

An important aspect of the revised Annex 1 is the development of an overall Contamination Control Strategy (CCS).

The CCS needs to serve as a cohesive outline of all the contamination control methods applied within the facility. Instead of considering contamination risks in isolation, manufacturers need to have an idea of how different aspects such as the design of the facility, equipment, personnel, materials, processes, cleaning, environment monitoring, and utilities interact in order to avoid contamination.

An effective CCS needs to be scientifically sound and developed through quality risk management. In addition, it must be evaluated and updated in case any new risks or changes arise.

Cleanroom Classification and Environmental Control

Cleanrooms are crucial to the manufacture of sterile products. Annex 1 provides guidance regarding classification of cleanrooms and environmental control, covering both requirements concerning particulate contamination and microbiological contamination.

Environmental conditions, such as air quality, temperature, humidity, pressure differential, and airflow have to be controlled by manufacturers. It is necessary to provide appropriate HEPA filtration and air handling system in order to achieve desired conditions of cleanroom.

Another vital part is the environmental monitoring. Environmental monitoring can vary depending on the zone and processes; it may include airborne particles, viable microorganisms, surface contamination, personnel monitoring and more.

Nevertheless, environmental monitoring should not be treated merely as an inspection activity. Analysis of data in order to detect possible trends that could influence product quality should be performed.



Personnel and Aseptic Practices

People constitute one of the most important sources of contamination within a cleanroom. As such, Annex 1 attaches a lot of importance to the training, qualification, gowning, hygiene, and conduct of personnel.

It is necessary for people handling the processes within a clean environment to know aseptic techniques and to always adhere to them. Gowning qualification should prove that the personnel knows how to put on their sterile attire and adhere to the correct practices while performing the process.

Avoiding any unnecessary interventions and movement is also critical. Each and every intervention should be carefully evaluated since each one of them may lead to contamination of the critical area.



Aseptic Processing and Barrier Technologies

The sterile manufacturing industry is now utilizing technologies that have been developed to reduce human intervention. RABS and isolators are among these technologies.

Barrier technology is one technology that offers physical barrier between the operators and the critical processing area, thereby reducing the risk of contamination. Annex 1 emphasizes the use of appropriate technologies and facility design that will reduce contamination risks and not depend on human interventions.

In the case of aseptic processing, it is also mandatory for the manufacturer to prove the process control through qualification, validation, monitoring, and reviews.

Pharmaceutical Water and Utilities

Water, gases, and other utilities could pose contamination risks if they are not properly designed and managed.

Manufacturers need to consider the microbiological and chemical quality of water systems used for sterile products, as well as the design of the system, its storage, distribution, and possible sources of contamination.

Other important utilities need to be examined in relation to their purpose and risk.



The Importance of Quality Risk Management

Quality Risk Management (QRM) is greatly emphasized in Annex 1, and it is essential that manufacturers identify contamination risks, assess their impact, establish proper controls, and evaluate the effectiveness of these controls.

This is an evolution from mere checklist management to a full quality management system.



Conclusion

Annex 1 of GMP goes beyond the mere provision of cleanroom requirements. It gives an overall framework of protection of sterile medicinal products from any contaminants during their lifetime cycle.

An effective application of Annex 1 requires an all-inclusive approach, which involves such issues as facility design, contamination control, personnel, equipment, utilities, environmental monitoring, aseptic processing, validation, and quality risk management.

In essence, the main objective of Annex 1 is clear and vital: to guarantee that sterile medicinal products are manufactured under proper conditions that pose no threat to consumers.

From this perspective, understanding and adhering to Annex 1 of GMP is not only a legal obligation for pharmaceutical companies; it is also an important aspect of their quality and safety.

Join our upcoming EU GMP ANNEX 1 Masterclass, where the crucial discussion on CQA will take place!

By Shara Najimudeen, Digital Marketing Executive, GLC Europe, Colombo Office, Sri Lanka.